James Maitland stands at the forefront of the intersection between medical robotics and the Internet of Things, bringing a visionary perspective to how we monitor and maintain the human body. With a career dedicated to developing high-fidelity sensors and integrated healthcare systems, he has become a leading voice in the shift from reactive medicine to proactive, tech-enabled prevention. This conversation delves into the recent $700 million expansion of Neko Health, examining how their proprietary hardware and massive data collection are set to redefine the American healthcare landscape. We explore the technological move away from traditional imaging like MRIs, the importance of long-term member engagement, and the rapid growth of a multi-billion dollar market driven by artificial intelligence and consumer demand for longevity.
Since your diagnostic process avoids traditional MRI machines in favor of proprietary sensors and blood analysis, how does this approach change the patient experience and the depth of data you can collect?
The move away from the claustrophobic, loud environment of a traditional MRI is a complete game-changer for the patient, turning a stressful medical chore into a streamlined, sixty-minute assessment. By utilizing proprietary sensors instead of high-radiation or magnetic resonance imaging, we create a non-invasive atmosphere where we can capture millions of health data points across the skin, heart, and metabolic systems without the typical friction of a hospital visit. Our next-generation hardware, specifically the Derma-2, Echo-2, and Spectrum-2 devices, allows us to scan skin markers and cardiovascular signals with a level of fidelity that traditional machines often miss in a general check-up. This isn’t just about comfort; it is about the sheer volume of signals we can process, from identifying pre-diabetes biomarkers to spotting the earliest risk factors for stroke or heart attack. When a person leaves their appointment, they aren’t waiting weeks for a letter; they get their results on-site and sit down for an in-person consultation with a medical professional immediately. It transforms the diagnostic journey into a collaborative dialogue rather than a cold, data-heavy report sent to a portal.
With a massive $700 million Series C funding round and the backing of high-profile figures from the worlds of tech and entertainment, what does this level of investment signal about the future of preventive health technology?
This $700 million influx, following a $260 million Series B round just months prior, is a massive vote of confidence in the shift toward democratized, high-tech prevention. When you see names like Mark Zuckerberg, Claudia Schiffer, and Maria Sharapova getting involved alongside heavy hitters like Lightspeed Venture Partners, it proves that the market sees preventive care not as a niche luxury, but as the next major pillar of global healthcare. We are moving into an era where “staying healthy” is a data-driven pursuit, and the capital being poured into this sector allows for the kind of research and development that makes prevention possible at a massive scale. The financial backing provides the runway to build our technology entirely in-house—everything from the physical medical devices to the consumer-facing software—ensuring we maintain total control over the user experience. It signals that the industry is ready to challenge the status quo, moving away from the $29.7 billion reactive market toward a future where we catch problems before they even start.
As you prepare to open your first clinic in New York City later this year, how do you plan to navigate the competitive and complex U.S. healthcare market compared to your existing operations in Sweden and the U.K.?
Entering the U.S. market is a pivotal step for us, especially given that the elective, direct-to-consumer scanning market is projected to skyrocket to over $47 billion by 2033. We aren’t just opening a clinic; we are introducing a new category of health experience to a population that is increasingly frustrated with the fragmented nature of traditional primary care. While competitors like Prenuvo and Ezra have established a footprint using AI-powered MRIs, our focus remains on our proprietary, radiation-free sensor technology and a price point that, in the U.K., sits at approximately £299. This competitive pricing, combined with the fact that we have over 350,000 people already on our waitlist or registered, shows that the demand for accessible, high-fidelity health data is universal. Our strategy in New York will mirror what has worked in London and Stockholm: providing a seamless, end-to-end experience that people actually want to return to. We’ve found that when the experience is frictionless, 75% of our members choose to book and prepay for their next scan right at the end of their appointment, which is a level of loyalty rarely seen in medical settings.
The next generation of Neko-engineered devices, such as the Derma-2 and Spectrum-2, promises higher fidelity in health signals; what specific clinical advantages do these hardware upgrades provide?
The leap to our latest generation of hardware represents a significant increase in the volume and precision of the data signals we can extract from the human body. For instance, the Echo-2 and Spectrum-2 are specifically tuned to pick up minute changes in heart and circulatory health that might go unnoticed in standard screenings, allowing us to identify subtle risk factors linked to metabolic syndrome. These upgrades mean we can track skin abnormalities and moles with much higher resolution, providing our medical professionals with the tools they need to catch potential issues during the very first scan. By building these devices in-house, we can iterate rapidly, deploying these high-fidelity sensors across all our clinics within just a few months of their debut. This allows us to continuously improve the accuracy of our assessments, ensuring that as our AI models ingest more data, the insights we provide to our 100,000-plus members become increasingly personalized. It’s about creating a “digital twin” of a person’s health that evolves every time they step into our clinic, making the transition from a single snapshot to a lifelong health narrative.
What is your forecast for the role of AI and integrated wearables in the evolution of full-body diagnostic scans over the next decade?
I believe we are rapidly approaching a point where the distinction between a clinical scan and daily health monitoring will virtually disappear through seamless data integration. We have already begun incorporating wearables integration and body composition analysis into our scans, which allows us to contextually layer a person’s daily activity and sleep data over the high-fidelity results from our clinic sensors. In the next decade, AI will move beyond just identifying anomalies to predicting health trajectories with startling accuracy, fueled by the $47.2 billion market expansion we expect to see by 2033. We will see a shift where these annual sixty-minute assessments serve as the “ground truth” for a person’s health, while their wearable devices provide the continuous stream of data in between. This ecosystem will empower individuals to see their health markers moving in the right direction in real-time, fundamentally changing our relationship with our own biology. Ultimately, the goal is to make disease a choice rather than an inevitability by providing the data and the medical guidance necessary to intervene years before a crisis occurs.
